Your browser doesn't support javascript.
loading
Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing.
Qayed, Muna; McGuirk, Joseph P; Myers, G Doug; Parameswaran, Vinod; Waller, Edmund K; Holman, Peter; Rodrigues, Margarida; Clough, Lee F; Willert, Jennifer.
  • Qayed M; Blood and Marrow Transplant Program, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia, USA. Electronic address: mqayed@emory.edu.
  • McGuirk JP; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Myers GD; Children's Mercy Hospital, Kansas City, Missouri, USA.
  • Parameswaran V; Avera Medical Group Hematology, Transplant & Cellular Therapy, Sioux Falls, South Dakota, USA.
  • Waller EK; Bone Marrow and Stem Cell Transplant Center, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.
  • Holman P; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Rodrigues M; Novartis Pharma AG, Basel, Switzerland.
  • Clough LF; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Willert J; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Cytotherapy ; 24(9): 869-878, 2022 09.
Article en En | MEDLINE | ID: mdl-35718701
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfoma de Células B / Leucemia-Linfoma Linfoblástico de Células Precursoras / Receptores Quiméricos de Antígenos Tipo de estudio: Guideline Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfoma de Células B / Leucemia-Linfoma Linfoblástico de Células Precursoras / Receptores Quiméricos de Antígenos Tipo de estudio: Guideline Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article